Association of Metabolic Syndrome with Serum Adipokines in Community-Living Elderly Japanese Women: Independent Association with Plasminogen Activator-Inhibitor-1

Abstract Disturbances in the thrombotic and fibrinolytic systems are a feature of insulin resistance, obesity, and the metabolic syndrome. However, there are few studies in which these relationships have been explored in mainly asymptomatic individuals using sophisticated measures of insulin sensitivity and regional adiposity. Variables of the hemostatic system were measured in 106 men (aged 32–68 yr; body mass index, 20–34 kg/m2). Insulin sensitivity was measured by minimal model analysis and regional adiposity by dual energy x-ray absorptiometry. Clustering of intercorrelated variables was assessed by the statistical technique of factor analysis. Plasma levels of procoagulant factors VII and X, anticoagulant proteins C and S, and plasminogen activator inhibitor-1 correlated positively with total and percent central body fat (r = 0.25–0.38; P < 0.05) and negatively with insulin sensitivity (except protein S; r = −0.24 to −0.35; P < 0.05). On factor analysis, procoagulant factors VII and X, proteins C and S, and plasminogen activator inhibitor-1 were components of the cluster of variables that explained the greatest proportion of the variance in the data (39.2%). Other variables included in this cluster were those typical of the metabolic syndrome and also serum γ-glutamyl transferase activity. These results suggest that factors VII and X and proteins C and S are features of the intercorrelated disturbances of the metabolic syndrome. Associations with adiposity and liver enzyme activity suggest the involvement of hepatic fat deposition.

Download Full-text

P12 Plasminogen activator inhibitor-1, thrombophilia in women with metabolic syndrome

Thrombosis Research ◽

10.1016/s0049-3848(09)70057-x ◽

2009 ◽

Vol 123 ◽

pp. S142

Author(s):

T.B. Pshenichnikova ◽

E.B. Perederyaeva

Keyword(s):

Metabolic Syndrome ◽

Plasminogen Activator ◽

Plasminogen Activator Inhibitor ◽

Plasminogen Activator Inhibitor 1 ◽

Activator Inhibitor

Download Full-text

Prevalence of Metabolic Syndrome and Related Characteristics in Obese Adolescents with and without Polycystic Ovary Syndrome

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2008-1198 ◽

2008 ◽

Vol 93 (12) ◽

pp. 4780-4786 ◽

Cited By ~ 72

Author(s):

Brooke Rossi ◽

Sara Sukalich ◽

Jennifer Droz ◽

Adam Griffin ◽

Stephen Cook ◽

...

Keyword(s):

Cardiovascular Disease ◽

Metabolic Syndrome ◽

Polycystic Ovary Syndrome ◽

Plasminogen Activator ◽

Polycystic Ovary ◽

Plasminogen Activator Inhibitor ◽

Plasminogen Activator Inhibitor 1 ◽

Ovary Syndrome ◽

Obese Adolescents ◽

Activator Inhibitor

Context: Adults with polycystic ovary syndrome (PCOS) may be at increased risk for metabolic syndrome (MBS) and related cardiovascular disease. It is not clear whether PCOS diagnosed in adolescence increases the risk of MBS in this age group. Objective: The aim was to compare the prevalence and related characteristics of MBS in obese adolescents with and without PCOS. Design: We conducted a cross-sectional study of overweight and obese PCOS adolescents and BMI matched controls. Patients and Participants: A total of 74 subjects, 43 with PCOS and 31 controls, participated in the study. Interventions: Each subject underwent a physical examination and laboratory evaluation for a diagnosis of MBS. Regional fat distribution was determined by computerized tomography scan in the PCOS adolescents. Main Outcome Measures: We measured the prevalence of MBS and its components in adolescent subjects and controls. Results: The PCOS group had larger ovarian volume and higher measures of total testosterone and free androgen index than controls, but there were no differences in waist circumference, fasting glucose, blood pressure, or lipids. PCOS adolescents demonstrated more glucose abnormalities and higher plasminogen activator inhibitor-1. By pediatric criteria, 53% of the PCOS and 55% of the control adolescents had MBS. By adult criteria, 26% of PCOS and 29% of controls met diagnostic criteria for MBS. Conclusions: Obese adolescent women have a high prevalence of MBS, and PCOS does not add additional risk for MBS. There appears to be an association between MBS and visceral adiposity. PCOS is associated with increased incidence of glucose intolerance and increased plasminogen activator inhibitor-1. Our results reinforce the importance of obesity counseling in adolescents to recognize the possible risk of future cardiovascular disease in these young women.

Download Full-text

Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with metabolic syndrome parameters in Malaysian subjects

Journal of Clinical Biochemistry and Nutrition ◽

10.3164/jcbn.11-48 ◽

2012 ◽

Vol 50 (3) ◽

pp. 184-189 ◽

Cited By ~ 7

Author(s):

Zaid H. Al-Hamodi ◽

Riyadh Saif-Ali ◽

Ikram S. Ismail ◽

Khaled A. Ahmed ◽

Sekaran Muniandy

Keyword(s):

Metabolic Syndrome ◽

Plasminogen Activator ◽

Plasminogen Activator Inhibitor ◽

Plasminogen Activator Inhibitor 1 ◽

Activator Inhibitor

Download Full-text

Assessment of plasminogen activator inhibitor-1 in obese Egyptian children

Egyptian Pediatric Association Gazette ◽

10.1186/s43054-019-0012-8 ◽

2020 ◽

Vol 68 (1) ◽

Author(s):

Marwa Farouk Mira ◽

Ghada Mohammad Anwar ◽

Azza Mohamed Sarry EL-Din ◽

Safinaz Mohammed Megahed

Keyword(s):

Metabolic Syndrome ◽

Plasminogen Activator ◽

Plasminogen Activator Inhibitor ◽

Anthropometric Measurements ◽

Obese Children ◽

Plasminogen Activator Inhibitor 1 ◽

Skin Fold Thickness ◽

Skin Fold ◽

Activator Inhibitor ◽

Pai 1

Abstract Background Plasminogen activator inhibitor-1 (PAI-1) is mainly produced in the liver and in the adipose tissue. Normal fibrin clearance mechanisms were found to be affected by high plasma PAI-1 levels and thus increases risk of thrombosis. The aim of the current study was to expound the childhood obesity effect on circulating PAI-1 and interpret the relation of PAI-1 to metabolic syndrome. This cross-sectional study was conducted on 43 obese children following in the Children Hospital and compared to 44 healthy sex- and age-matched controls. All recruited cohort are subjected to anthropometric measurements: weight, height, BMI, waist circumference, hip circumference, and skin fold thickness (biceps, triceps, and subscapular), and laboratory investigations in the form of lipid profile, fasting blood sugar, fasting insulin, insulin resistance estimated by HOMA-IR, and plasminogen activator inhibitor-1. Results The level of plasminogen activator inhibitor-1 in the obese group was significantly higher than that in the control group (47.98 ± 17.42 vs. 28.00 ± 11.35 respectively). PAI-1 showed positive significant correlation to anthropometric measurements: BMI (p = 0.000), weight (p = 0.000), biceps skin fold thickness (p = 0.04), triceps skin fold thickness (p = 0.4), and subscapular skin fold thickness (p = 0.04). Also, a significant positive correlation was found between PAI-1 and systolic (p = 0.000) and diastolic blood pressure (p = 0.04). Positive correlations were found between PAI-1 and cholesterol (p = 0.000), triglycerides (p = 0.02), LDL-c (p = 0.000), insulin (p = 0.000), and HOMA-IR (r = 0.5, p = 0.02). Conclusion Fat mass accumulation is related to high PAI-1 levels, which might in turn contribute to cardiovascular risk. Plasminogen Activator Inhibitor-1 is a good predictive test for metabolic syndrome in obese children.

Download Full-text